DBP B Stock Overview
A pharmaceutical company, engages in the development and commercialization of approaches for the treatment of oncological, infectious, autoimmune, and other life-threatening diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Double Bond Pharmaceutical International AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.42 |
| 52 Week High | SEK 0.99 |
| 52 Week Low | SEK 0.26 |
| Beta | 0.65 |
| 11 Month Change | 33.75% |
| 3 Month Change | 6.27% |
| 1 Year Change | 18.11% |
| 33 Year Change | -64.31% |
| 5 Year Change | -88.57% |
| Change since IPO | -90.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| DBP B | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 21.8% | 0.9% | -0.2% |
| 1Y | 18.1% | 9.3% | 11.8% |
Return vs Industry: DBP B exceeded the Swedish Pharmaceuticals industry which returned 9.3% over the past year.
Return vs Market: DBP B exceeded the Swedish Market which returned 11.8% over the past year.
Price Volatility
| DBP B volatility | |
|---|---|
| DBP B Average Weekly Movement | 16.7% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: DBP B's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: DBP B's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 10 | Igor Lokot | www.doublebp.com |
Double Bond Pharmaceutical International AB (publ), a pharmaceutical company, engages in the development and commercialization of approaches for the treatment of oncological, infectious, autoimmune, and other life-threatening diseases. It offers Temodex, a therapy to treat malignant brain tumors; and SA033, a therapy to treat cancers in liver. The company is also developing Belopenem for the treatment of bacterial pneumonia.
Double Bond Pharmaceutical International AB (publ) Fundamentals Summary
| DBP B fundamental statistics | |
|---|---|
| Market cap | SEK 45.42m |
| Earnings (TTM) | -SEK 16.75m |
| Revenue (TTM) | SEK 1.20m |
37.8x
P/S Ratio-2.7x
P/E RatioIs DBP B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DBP B income statement (TTM) | |
|---|---|
| Revenue | SEK 1.20m |
| Cost of Revenue | SEK 2.54m |
| Gross Profit | -SEK 1.34m |
| Other Expenses | SEK 15.40m |
| Earnings | -SEK 16.75m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 25, 2024
| Earnings per share (EPS) | -0.16 |
| Gross Margin | -111.94% |
| Net Profit Margin | -1,395.48% |
| Debt/Equity Ratio | 0% |
How did DBP B perform over the long term?
See historical performance and comparison